AD symptom relief by fucoidan was mechanistically confirmed to involve the reduced mRNA expression of TARC, MDC, and RANTES in IFN-γ/TNF-α-exposed keratinocytes, decreased epidermal thickening, and inhibited mast cell infiltration [32]. This evidence concerns the gene CCL17 and Alzheimer disease.